The Vaccines and Related Biological Products advisory committee (VRBPAC) voted unanimously that the available data supported the efficacy of RSVpreF in helping to protect against the complications of RSV in infants from birth to six months of age.
The committee also voted ten to four that the data supported the safety of the candidate.
RSV is a contagious virus characterised by several mild, cold-like symptoms. Although most people recover within a week or two, the virus can potentially cause severe illness in young infants, older adults and individuals with certain chronic medical conditions.
